Corporate Update Sparks Debate: Recent discussions on social media about Travere Therapeutics have centered on the company’s latest corporate update and 2026 outlook. Many users highlighted the strong Q4 sales figures and significant growth in FILSPARI revenue, seeing it as a positive sign for future performance. However, the stock’s sharp decline has fueled intense conversation.
FDA Concerns Weigh Heavy: A major point of contention online is the FDA’s request for additional data on the clinical benefits of Travere’s kidney disease treatment, causing a reported pre-market drop of over 28%. Commenters are split, with some expressing frustration over potential delays in approval, while others remain hopeful about the therapy’s long-term prospects. The uncertainty has kept the dialogue heated and dynamic.
Note: This discussion summary was generated from an AI condensation of post data.
Travere Therapeutics Insider Trading Activity
Travere Therapeutics insiders have traded $TVTX stock on the open market 18 times in the past 6 months. Of those trades, 0 have been purchases and 18 have been sales.
Here’s a breakdown of recent trading of $TVTX stock by insiders over the last 6 months:
- ERIC M DUBE (CHIEF EXECUTIVE OFFICER) has made 0 purchases and 2 sales selling 120,000 shares for an estimated $3,638,432.
- SANDRA CALVIN (SVP, CHIEF ACCOUNTING OFFICER) has made 0 purchases and 3 sales selling 77,427 shares for an estimated $2,816,980.
- WILLIAM E. ROTE (Chief Research Officer) sold 60,000 shares for an estimated $2,406,180
- JULA INRIG (CHIEF MEDICAL OFFICER) has made 0 purchases and 3 sales selling 17,476 shares for an estimated $728,408.
- CHRISTOPHER R. CLINE (CHIEF FINANCIAL OFFICER) has made 0 purchases and 4 sales selling 21,043 shares for an estimated $718,945.
- TIMOTHY COUGHLIN sold 18,000 shares for an estimated $630,601
- PETER HEERMA (CHIEF COMMERCIAL OFFICER) has made 0 purchases and 3 sales selling 13,233 shares for an estimated $474,745.
- ELIZABETH E REED (Chief Legal Officer and GC) sold 10,000 shares for an estimated $250,000
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Travere Therapeutics Revenue
Travere Therapeutics had revenues of $164.9M in Q3 2025. This is an increase of 162.11% from the same period in the prior year.
You can track TVTX financials on Quiver Quantitative's TVTX stock page.
Travere Therapeutics Hedge Fund Activity
We have seen 125 institutional investors add shares of Travere Therapeutics stock to their portfolio, and 101 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PERCEPTIVE ADVISORS LLC added 2,960,363 shares (+354.9%) to their portfolio in Q3 2025, for an estimated $70,752,675
- ARMISTICE CAPITAL, LLC removed 2,152,000 shares (-24.2%) from their portfolio in Q3 2025, for an estimated $51,432,800
- FMR LLC added 1,826,375 shares (+171.0%) to their portfolio in Q3 2025, for an estimated $43,650,362
- STEPHENS INVESTMENT MANAGEMENT GROUP LLC added 1,599,668 shares (+inf%) to their portfolio in Q3 2025, for an estimated $38,232,065
- WELLINGTON MANAGEMENT GROUP LLP added 1,166,460 shares (+3331.9%) to their portfolio in Q3 2025, for an estimated $27,878,394
- DEUTSCHE BANK AG\ added 1,082,747 shares (+209.6%) to their portfolio in Q3 2025, for an estimated $25,877,653
- JANUS HENDERSON GROUP PLC added 1,058,390 shares (+11.1%) to their portfolio in Q3 2025, for an estimated $25,295,521
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Travere Therapeutics Analyst Ratings
Wall Street analysts have issued reports on $TVTX in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 11/28/2025
- TD Cowen issued a "Buy" rating on 10/31/2025
- Wells Fargo issued a "Overweight" rating on 09/11/2025
- Wedbush issued a "Outperform" rating on 08/07/2025
- Scotiabank issued a "Sector Outperform" rating on 08/07/2025
To track analyst ratings and price targets for Travere Therapeutics, check out Quiver Quantitative's $TVTX forecast page.
Travere Therapeutics Price Targets
Multiple analysts have issued price targets for $TVTX recently. We have seen 7 analysts offer price targets for $TVTX in the last 6 months, with a median target of $35.0.
Here are some recent targets:
- Joseph Pantginis from HC Wainwright & Co. set a target price of $47.0 on 11/28/2025
- Allison Bratzel from Piper Sandler set a target price of $35.0 on 11/04/2025
- Tyler Van Buren from TD Cowen set a target price of $40.0 on 10/31/2025
- Alex Thompson from Stifel set a target price of $25.0 on 09/12/2025
- Mohit Bansal from Wells Fargo set a target price of $35.0 on 09/11/2025
- Greg Harrison from Scotiabank set a target price of $31.0 on 08/07/2025
- Laura Chico from Wedbush set a target price of $32.0 on 08/07/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
